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Introduction
One of the more surprising aspects of normal physi-
ology appreciated only in recent years is that sensors
for critical circulating substances can be located in
rather surprising anatomical sites and that these can
communicate to target organs in nonclassic ways.
For example, glucose homeostasis requires that 
sensing units constantly monitor blood glucose con-
centrations and modulate food intake and glucose
use or production. For many years it has been recog-
nized that pancreatic β cells possess a well-character-
ized glucose sensor, which is activated by rises in
blood glucose and which induces the secretion of
insulin, the hormone most important to the deter-
mination of glucose use. Similarly, secretion of
glucagon to accelerate hepatic glucose production is
triggered by a sensor, which responds to hypo-
glycemia, present in pancreatic α cells. This secreto-
ry activity is also under the control of the autonom-
ic nervous system. Discrete glucose sensors located in
the hypothalamus and the brain stem modulate the
activity of the autonomic nervous system and regu-
late feeding and glucose homeostasis.
More recently, the hepatoportal vein has been
shown to contain a metabolic sensor that is activated
when a glucose gradient is established between the
portal vein and the hepatic artery. This sensor stimu-
lates hepatic glucose uptake (1–3), inhibits food
intake (4, 5), and blocks the secretion of counterregu-
latory hormones (6, 7). These actions are thought to
cooperate to minimize postprandial glycemic excur-
sions and regulate termination of food intake.
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Recent evidence suggests the existence of a hepatoportal vein glucose sensor, whose activation
leads to enhanced glucose use in skeletal muscle, heart, and brown adipose tissue. The mecha-
nism leading to this increase in whole body glucose clearance is not known, but previous data sug-
gest that it is insulin independent. Here, we sought to further determine the portal sensor sig-
naling pathway by selectively evaluating its dependence on muscle GLUT4, insulin receptor, and
the evolutionarily conserved sensor of metabolic stress, AMP-activated protein kinase (AMPK).
We demonstrate that the increase in muscle glucose use was suppressed in mice lacking the
expression of GLUT4 in the organ muscle. In contrast, glucose use was stimulated normally in
mice with muscle-specific inactivation of the insulin receptor gene, confirming independence
from insulin-signaling pathways. Most importantly, the muscle glucose use in response to acti-
vation of the hepatoportal vein glucose sensor was completely dependent on the activity of AMPK,
because enhanced hexose disposal was prevented by expression of a dominant negative AMPK in
muscle. These data demonstrate that the portal sensor induces glucose use and development of
hypoglycemia independently of insulin action, but by a mechanism that requires activation of the
AMPK and the presence of GLUT4.
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Despite clear evidence of the multiple roles of this
sensor, numerous questions are still unanswered,
including its cellular composition, the way it trans-
mits its signal to target tissues, and the signaling
pathways activated at the target tissue level.
In our previous studies (8), we demonstrated that
activation of the hepatoportal sensor by a portal glu-
cose infusion led to development of hypoglycemia.
This was due to a stimulation of glucose clearance,
which was most evident in heart, soleus, and brown
adipose tissue. Some information is available con-
cerning the pathway involved in glucose sensing in
the hepatoportal circulation. For example, activation
of this sensor requires the presence of the glucose
transporter isoform GLUT2 (9). Indeed, hypo-
glycemia and increased glucose clearance could no
longer be triggered by portal vein glucose infusion in
mice with a β cell–specific transgenic expression of
GLUT1 to restore a normal insulin secretory function,
but with an inactive endogenous GLUT2 gene (10).
Furthermore, a functional GLP-1 receptor is required
for the glucose competence of the sensor. Indeed, acti-
vation by portal glucose infusion is blocked by coin-
fusion of the GLP-1 antagonist exendin-(9-39) and is
undetectable in GLP-1 receptor knockout mice (11).
In marked contrast, essentially nothing is known con-
cerning the mechanism by which the hepatoportal
sensor activates glucose clearance. It is likely not due
to enhanced stimulation of insulin secretion, howev-
er, since plasma insulin levels were similar when glu-
cose was infused into the portal or the femoral veins
(8), though the latter route of glucose administration
was associated with a transient hyperglycemia instead
of development of hypoglycemia. It is still possible,
however, that sensitization to the action of insulin
explains the increase in glucose use or that the process
is insulin-independent.
The increase in glucose uptake by muscle in
response to insulin or contraction depends on the
translocation of intracellular GLUT4 containing vesi-
cles to, and fusion with, the plasma membrane
(12–15). Following contraction or hypoxia, the
increase in hexose uptake into muscle appears to rely
on the activation of 5′-AMP–activated kinase
(AMPK). The role of this kinase on the translocation
of GLUT4 to the plasma membrane has been demon-
strated using AICAR, an activator of AMP kinase,
which induces surface expression of the transporter
and increases the rate of glucose uptake (16–19). In
vivo administration of this substance also induces
hypoglycemia (16, 18). More recently, mice express-
ing a transgene encoding a dominant negative form
of the α2 subunit of AMPK specifically in muscle dis-
played decreased GLUT4 translocation and glucose
uptake following contraction (20).
Finally, it has been reported that insulin could still
stimulate glucose uptake in the soleus of GLUT4–/–
mice (21). This suggests that other transporter iso-
forms may be implicated in this insulin-stimulated
response, although such increase in glucose uptake was
not confirmed in mice with muscle-specific inactiva-
tion of GLUT4 (22). Nevertheless, the recent identifi-
cation of novel members of the glucose transporter
family and their localization in muscles (23, 24) sug-
gests that GLUT4-independent activation of muscle
glucose uptake could exist.
The aim of the present study was to determine,
using mice with muscle-specific gene modifications,
the mechanisms by which the hepatoportal sensor
signal activates glucose uptake in muscle. We deter-
mined that stimulated uptake was dependent on the
expression of GLUT4 and was independent of the
presence of an insulin receptor, but required activa-
tion of AMP-activated kinase.
Methods
Mice and surgical procedures for catheter implantation. The
MGLUT4 KO (muscle-only GLUT4 gene inactivation)
(22), MIRKO (muscle-specific insulin receptor gene
inactivation) (25), and AMPK-DN (muscle-specific
transgenic expression of a dominant negative form of
AMP kinase) (20) mice were in SV129×C57Bl/6J×FVB,
SV129×CD1×FVB, and C57Bl/6J background, respec-
tively. The control mice used in each experiment were
the littermates of the respective mutant mice. Under
pentobarbital anesthesia (65 mg/kg intraperitoneal-
ly) a first catheter was implanted into the hepatopor-
tal vein through the splenic vein of 12- to 16-week-old
female control and mutant mice, as described (11).
After 4–6 days, allowing body weight recovery, one
extremity of a second catheter was implanted into the
femoral vein under similar anesthesia. The other
extremity of the catheter was tunneled under the skin
of the back, exteriorized, and secured in place at the
back of the neck. The mice were then allowed to recov-
er from the surgery in individual cages.
Infusion procedures. Five to 7 days after catheter
implantation the mice were fasted for 6 h. Saline or glu-
cose was infused for 180 min either through the portal
vein, at a rate of approximately 25 mg/kg/min (2 µl/
min), which corresponds to the mean value of the
endogenous glucose production rate in 6-h fasted 30-g
mice, as described (8, 9, 11).
To determine the whole body glucose clearance rate
HPLC-purified D-(3H)3-glucose (NEN Life Science
Products Inc., Boston, Massachusetts, USA) was in-
fused continuously through the femoral vein at a rate
of 10 µCi/kg/min. Plasma glucose and D-(3H)3-glucose
concentrations were determined in 5 µl of blood sam-
pled from the tip of the tail vein each 20 min following
the initiation of infusion. These methods have been val-
idated previously (8, 9, 11).
Glucose use index in individual tissues. To determine an
index for the individual tissue glucose use rate, a flash
injection of 1 µCi per mouse of 14C-2-deoxyglucose
(14C-2DG; NEN Life Science Products Inc.) through the
femoral vein was performed 60 min before the end of
the infusions. Plasma 14C-2DG disappearance was
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determined in 5-µl drops of blood sampled from the
tip of the tail vein at 0, 5, 10, 15, 20, 25, 30, 45, and 60
min after the injection.
Analytical procedures. Blood glucose concentration
was determined during the infusions using a glucose
meter (Roche Diagnostics A/G, Basel, Switzerland).
Plasma insulin was determined using an ELISA kit
(Mercodia, Uppsala, Sweden) before and at 10, 30, 50,
120, 180 min following the beginning of the infu-
sions in 5 µl of plasma from 15 µl of blood collected
from the tail tip (8).
Isotope measurements. Plasma D-(3H-3)glucose enrich-
ment was determined from total blood after depro-
teinization (8) using ZnSO4 and Ba(OH)2 solutions to
precipitate the proteins and blood cells. The Zn(OH)2
precipitate formed was spun down. An aliquot of the
supernatant was evaporated to dryness to determine
the radioactivity corresponding to D-(3H-3)glucose. In
another aliquot of the same supernatant glucose con-
centration was assessed by the glucose oxidase
method (Trinder; Sigma-Aldrich, St. Louis, Missouri,
USA). Tissue 14C-2DG and 14C-2DG-6 phosphate con-
tent were determined as described previously (8).
Briefly, a piece of each tissue was dissolved in 1 M
NaOH at 55°C for 60–120 min, then neutralized
with 1 M hydrochloric acid. 14C-2DG-6-phosphate
and 14C-2DG were differentially precipitated by the
use of a zinc hydroxide (0.3 M) precipitation or a per-
chloric acid solution (6%) (8).
Calculations. Calculations were made with parameters
collected during the last 60 min of the infusions when
a steady state D-(3H)3-glucose enrichment was
obtained. First, glucose turnover was calculated by
dividing the D-(3H)3-glucose infusion rate by the plas-
ma glucose-specific activity as described (8). The mean
was calculated for each time point of this period. 
Second, whole body glucose clearance (ml/kg/min)
was calculated by dividing the mean glucose turnover
rate by the mean blood glucose concentration
obtained during the last hour of the infusion. The
mean value of mice from the same group was report-
ed. The area under the curve (AUC) was calculated for
blood glucose and plasma insulin concentrations
obtained during the infusion period. To calculate the
blood glucose AUC of each mouse, the fasting value
was subtracted from each concentration of glucose
determined every 20 min (t) after the beginning of the
infusion and every 20 min until completion. The mean
values between t and at t + 20 min were calculated, and
the new values were multiplied by 20 min, which cor-
responds to the time period between two samplings.
To calculate the area under the plasma insulin curve
the fasted insulinemia was subtracted from each value
determined at 10, 30, 50, 120, and 180 minutes. The
mean values between t and at the corresponding next
time period were calculated, and the new values were
multiplied by the time length (minutes) between two
samplings. These data were then added together to
obtain the glucose and insulin areas under the curve.
Statistical analysis. Results are presented as mean plus
or minus SE. Statistical significance of differences was
analyzed using Student t test for unpaired bilaterally
distributed values of unequal variance. Values were
considered different from each other when P values
were less than 0.05.
Results
Time course of blood glucose levels during hepatoportal glu-
cose infusions. To evaluate the mechanism by which
the hepatoportal sensor activates glucose use in
muscle, we studied mice with muscle-specific dele-
tion of GLUT4 (MGLUT4 KO mice), the insulin
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Figure 1
Glycemic profiles of MGLUT4, MIRKO, and AMPK-DN mice and their respective controls infused with glucose into the portal vein. Glucose was
infused through the portal vein in control (open squares) and mutant mice (filled squares) for 180 min at a rate of ∼25 mg/kg/min. The means
± SE of blood glucose was measured every 20 min. The insets depict the corresponding AUC (mM) for the different groups of mice. (a) MGLUT4
mice; (b) MIRKO mice; (c) AMPK-DN mice. Eight to ten mice were studied per group. *Statistically different from controls; P < 0.05.
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receptor (MIRKO mice), or with transgenic overex-
pression of a dominant negative form of the AMP
kinase (AMPK-DN mice) and their respective con-
trols. These mice were infused with glucose into the
hepatoportal vein and the glycemic profiles were fol-
lowed over a period of 3 h. As reported previously,
hypoglycemia developed progressively in the three
different control lines (Figure 1 and Table 1). The
extent of hypoglycemia reached at completion of the
glucose-infusion periods differed somewhat between
the different control mice (2.8 ± 0.2, 3.3 ± 0.1, and 3.4
± 0.2 mM in MGLUT4 KO, MIRKO, AMPK-DN con-
trol mice, respectively) probably due to differences
in their genetic backgrounds. Similar differences
have been reported previously (8, 11).
The glycemic profile of MGLUT4 KO mice infused
with glucose into the portal vein was characterized,
first, by a slightly higher glycemia in the fasted state
(Figure 1a). Second, hyperglycemia developed to reach
a maximum of 8.3 ± 0.6 mM after 60 min of glucose
infusion and then progressively decreased, but
remained higher than that of controls at the end of the
experiment. The glucose AUC was negative in control
and positive in the MGLUT4 KO mice.
When glucose was infused into the portal vein of the
MIRKO mice, hypoglycemia developed similarly to the
controls, and the corresponding glucose AUCs were
negative and not different from each other (Figure 1b).
When MIRKO mice and their respective controls were
infused with glucose through the femoral vein, hyper-
glycemia transiently developed and returned to the pre-
infusion value after 3 h (data not shown), and no dif-
ferences were noted between both groups of mice. This
indicated that hypoglycemia induced in portal vein glu-
cose–infused MIRKO mice was due to specific stimu-
lation of the portal sensor.
The infusion of glucose into the portal vein of the
AMPK-DN mice did not induce hypoglycemia (Figure
1c). In contrast, glycemia increased and reached a max-
imum (7.4 ± 0.1 mM) after 20 minutes, then decreased
very progressively to 5.7 ± 0.4 mM at completion of the
glucose infusion, but remained higher than in the fast-
ed state. The AUC of the AMPK-DN mice was positive
and significantly higher than that of the corresponding
controls. A similar glucose infusion was also performed
through the femoral vein (not shown). The blood glu-
cose profiles were similar to each other and showed a
transient hyperglycemia followed by a return of the
glycemia toward the fasted levels.
Glucose clearance rates during hepatoportal glucose infu-
sions. To evaluate if the different blood glucose profiles
were associated with variations of the glucose turnover
rates glucose or saline was infused into the portal vein
while 3H-glucose was infused through the femoral vein.
Measurement of isotopic dilution allowed determina-
tion of whole body glucose turnover and calculation of
glucose clearance (Figure 2). The glucose clearance
rates of glucose-infused control mice were similar in all
groups (79.6 ± 11.4; 85.0 ± 6.6; 66.4 ± 3.9 ml/kg/min in
MGLUT4, MIRKO, and AMPK-DN control mice,
respectively). The glucose clearance rate was reduced in
the MGLUT4 by 45% as compared with their respective
controls. Glucose clearance was similar to the control
value for the MIRKO mice and reduced by more than
50% in the AMPK-DN mice relative to control mice.
Glucose clearance rates were higher in the glucose-
infused than in the saline-infused mice in all groups of
control animals.
Plasma insulin concentrations during hepatoportal glu-
cose infusions. Plasma insulin concentrations were
assessed in all groups of mice before and 10, 30, 50,
120, and 180 minutes after the beginning of glucose
infusion into the hepatoportal vein. Plasma insulin
increased in every group and remained elevated dur-
ing the entire infusion period (Figure 3 and Table 1).
The absolute value of plasma insulin secretion, how-
ever, was different, according to the strain of mice
studied. When glucose was infused in the MGLUT4
mice, plasma insulin levels rose to reach a maximum
at 50 min (Figure 3a) and remains high until com-
pletion of the experiment. The AUC and the plasma
insulin levels were significantly higher in the
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Table 1
Blood glucose and plasma insulin concentrations during portal saline or glucose infusions in control and mutant mice
MGLUT4 MIRKO AMPK-DN
T0 T180 T0 T180 T0 T180
Saline infused
Glucose (mM) Controls 5.0 ± 0.4 3.8 ± 0.8 5.2 ± 0.6 4.4 ± 0.4 5.3 ± 0.9 4.1 ± 0.6
Mutants 6.1 ± 0.7 4.5 ± 0.8 5.8 ± 0.8 4.0 ± 0.9 5.3 ± 0.7 4.9 ± 0.7
Insulin (µU/ml) Controls NA NA NA NA NA NA
Mutants NA NA NA NA NA NA
Glucose infused
Glucose (mM) Controls 4.8 ± 0.7 2.8 ± 0.2 5.3 ± 0.3 3.3 ± 0.1 5.3 ± 0.1 3.4 ± 0.2
Mutants 5.9 ± 0.5 4.0 ± 0.5 5.7 ± 0.3 3.2 ± 0.2 5.8 ± 0.2 5.7 ± 0.4
Insulin (µU/ml) Controls 16.1 ± 2.3 20.5 ± 4.2 9.3 ± 1.7 19.6 ± 1.9 10.6 ± 0.5 15.1 ± 1.3
Mutants 18.9 ± 1.2 32.5 ± 2.3A 16.0 ± 1.7 22.3 ± 9.4 9.5 ± 0.5 21.1 ± 3.7
AStatistically different from controls; P < 0.05.
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MGLUT4 than in the corresponding control mice
after 30, 50, and at 180 min. Interestingly, plasma
insulin concentration was higher in the fasted state
in the MIRKO as compared with control mice, but
did not increase over time during the glucose infu-
sion. Hence, the corresponding AUC, an index of the
increased insulinemia during the infusion, was very
small when compared with the corresponding con-
trols (Figure 3b). The plasma insulin concentration
of the AMPK-DN glucose–infused mice rose and
reached values similar to the corresponding controls
(Figure 3c), even though the blood glucose levels
were higher in the mutant as compared with the con-
trol mice. At present, we do not have any explanation
for this discrepancy between glucose and insulin lev-
els in the mutant mice.
Individual tissue glucose use. To evaluate if the reduced
glucose turnover rate of the glucose-infused MGLUT4
mice was associated with a decreased muscle glucose
use we injected 14C-2DG in the MGLUT4 and the cor-
responding control mice 2 h after the initiation of the
portal vein glucose infusion. The glucose use rates
were lower in all the muscles of MGLUT4 mice as com-
pared with the corresponding controls (Figure 4a).
Conversely, the glucose use rate was normal in white
and brown adipose tissues and the skin. In the MIRKO
mice, no differences were noted for any tissue, except
in white adipose tissue, between the control and
MIRKO mice (Figure 4b). In the AMPK-DN mice,
when compared with controls, the glucose use rate was
reduced in most of the muscles but not in adipose tis-
sues where it was similar (Figure 4c).
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Figure 2
Blood glucose clearance of MGLUT4, MIRKO, and AMPK-DN mice
and their respective controls infused with saline or glucose into the
portal vein. Saline or glucose was infused through the portal vein in
controls (white bars) and mutant mice (black bars) for 180 min at a
rate of ∼25 mg/kg/min. A tritiated glucose coinfusion was performed
to calculate whole body glucose turnover. Glucose clearance rates
were then calculated as mean ± SE (ml/kg/min). Glucose-infused
mice were studied in groups of eight to ten, and saline-infused mice
were studied in groups of three to four. *Statistically different from
controls; P < 0.05.
Figure 3
Plasma insulin levels of MGLUT4, MIRKO, and AMPK-DN mice and their respective controls infused with glucose into the portal vein. Glu-
cose was infused through the portal vein in control (white bars) and mutant mice (black bars) for 180 min at a rate of ∼25 mg/kg/min. Plas-
ma insulin levels were determined from the tip of the tail vein before and 10, 30, 50, 120, and 180 min after the beginning of the glucose
infusion and are reported as mean ± SE for eight to ten mice per group. The insets depict the corresponding AUC (µU/min/ml) for the dif-
ferent groups of mice. (a) MGLUT4 mice; (b) MIRKO mice; (c) AMPK-DN mice. *Statistically different from controls; P < 0.05.
Downloaded from http://www.jci.org on January 24, 2017.   https://doi.org/10.1172/JCI16888
Discussion
Glucose infusion into the hepatoportal vein stimulates
glucose use in muscle and brown adipose tissue and
leads to development of hypoglycemia. In the present
study, using genetically modified mice we show that
the signal transmitted by the hepatoportal sensor
depends on muscle expression of GLUT4 and the
AMPK, but not on the presence of an insulin receptor.
The role of GLUT4 in hepatoportal sensor–stimu-
lated muscle glucose use was evaluated in mice with
muscle-specific inactivation of GLUT4. Infusion of
glucose into the portal vein of these mice induced a
glycemic profile characterized by a transient rise in
blood glucose concentration, which was very similar
to that observed when glucose was infused in the
femoral vein, i.e., without activation of the hepatopor-
tal sensor (8). In addition, the glucose clearance rate
was lower than for the corresponding controls. It was,
nevertheless, higher than in the saline-infused mice.
Individual tissue glucose use was reduced in all mus-
cles, but not in the adipose tissues. Taken together,
these data show that maximal activation by the
hepatoportal glucose sensor of muscle glucose use
requires the presence of GLUT4 in this tissue. Never-
theless, since glucose clearance was not reduced to the
level of saline-infused mice, whereas it was reduced to
this level in AMPK mutant mice, this suggests that
other glucose transporters could participate in muscle
glucose use in response to the activation of the hepato-
portal sensor. The identity of these transporters is not
known but they may belong to the family of recently
cloned transporter isoforms (23, 24).
Another possible explanation for the decreased por-
tal sensor–stimulated clearance in MGLUT4 mice
could be related to the reported glucotoxicity-
induced insulin resistance that develops on these
mice (25). In this cited study, however, this secondary
complication was seen only in aged male mice. Here,
we used younger female mice, which had homoge-
nous, nondiabetic, blood glucose levels and which did
not display glutotoxicity-induced insulin resistance,
as confirmed by normal rates of 14C-2DG uptake in
white and brown adipose tissue during the portal vein
glucose infusion (Figure 4a). Thus, impairment of
glucose clearance secondary to glucotoxicity is unlike-
ly to explain any of the modifications in the parame-
ters we measured.
In MIRKO mice, hypoglycemia developed as in the
corresponding control animals. In addition, glucose
clearance was increased to the same extent in both
groups of mice. These data strongly suggest that mus-
cle glucose use activated by the portal vein sensor is
insulin-independent. This observation may also
explain the previous report that MIRKO mice have a
normal tolerance to an intraperitoneal glucose
administration (26). In this particular situation, glu-
cose is rapidly collected into the portal vein where it
stimulates the glucose sensor and, consequently,
induces glucose uptake in muscle. Earlier data show-
ing that intraperitoneal glucose injection–induced
transient hypoglycemia in the rat (5) are compatible
with this interpretation.
The insulin-independent increase in GLUT4-
dependent muscle glucose use indicates that an alter-
native intracellular signaling pathway must be acti-
vated to stimulate GLUT4 translocation to the
plasma membrane. AMPK appears to play an essen-
tial role in stimulating GLUT4 translocation during
contraction or hypoxia (16, 20, 27). To determine if
AMPK was recruited following activation of the
hepatoportal sensor, we used mice expressing a dom-
inant negative AMPK transgene in muscle (20). Glu-
cose infusion into the portal vein of these mice led to
development of hyperglycemia, which persisted
throughout the glucose infusion. In addition, the
glucose clearance rate was reduced almost to the level
of the saline-infused mice. Individual muscle glucose
use was also reduced in muscles of the AMPK-DN
mice. These data thus indicate that muscle AMPK is
a key signaling intermediate in the transmission of
the signal generated at the portal sensor. This is also
supported by the observation that the activity of the
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Figure 4
Glucose use rates of MGLUT4, MIRKO, and AMPK-DN mice and their respective controls infused with glucose into the portal vein. Glucose
was infused through the portal vein in control (white bars) and mutant mice (black bars) for 180 min at a rate of ∼25 mg/kg/min. A 14C-2DG
injection protocol was used to determine glucose use (ng/mg/min) by the diaphragm (Dia), the heart (Hea), the soleus muscle (Sol), the tib-
ialis anterior (Tib) the vastus lateralis (VL), the white gonadal tissue (WAT), the brown interscapular adipose tissue (BAT), and the skin. (a)
MGLUT4 mice; (b) MIRKO mice; (c) AMPK-DN mice. Eight to ten mice per group were studied. *Statistically different from controls; P < 0.05.
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α2-AMP–activated kinase was increased 20% at the
end of the 3-h infusion period in the heart and mus-
cles of the portal glucose–infused mice, although the
difference did not reach statistical significance (not
shown). Further analysis of AMPK activation by
Western blot analysis of its phosphorylated form per-
formed at 20, 60, and 180 min after initiation of por-
tal vein glucose infusion did not show statistically
significant increased phosphorylation. This is, how-
ever, not too surprising when considering that the
kinetics of hypoglycemia induction is slow and much
slower than that induced by AICAR administration.
Also, there was a basal level of AMPK phosphoryla-
tion in saline-infused mouse muscle. This could be
due to the fact that the mice were starved for 6 h
before the beginning of the experiment and probably
also to the stress and hypoxia induced by the surgical
and muscle isolation procedures. Thus, a small acti-
vation of AMP kinase by the activated portal sensor
may be masked. Nevertheless, our data indicate that
activity of the AMP kinase is required in muscle for
portal vein sensor–stimulated glucose uptake.
Recent studies described activation of muscle
AMPK by an intracerebroventricular injection of lep-
tin (28, 29). In addition, we and others, have shown
that leptin stimulates muscle glucose use (30–32).
These mechanisms involved the activation of the
autonomic nervous system, as does the activation of
the hepatoportal sensor transmitting the glucose sig-
nal toward the target tissues. These data reinforce our
hypothesis that the AMP-activated kinase is involved
in the activation of muscle glucose use by the activat-
ed hepatoportal glucose sensor.
In conclusion, the present study extends our under-
standing of the regulation of glucose use in muscles
by the hepatoportal glucose sensor. First, our previ-
ous studies using mutant mice demonstrated that
this sensor was GLUT2 dependent and required the
presence of an activated GLP-1 receptor for full glu-
cose competence. This sensor was also inhibited by
somatostatin (8). Electrophysiological studies have
demonstrated that activation of the portal sensor by
glucose leads to changes in the firing rate of hepatic
afferent branches of the vagus nerve (33, 34). These
project to the nucleus of the tractus solitarius and
the ventromedial and lateral hypothalamus (28, 35,
36). There is thus a direct connection between the
portal sensor and central brain areas involved in the
control of the autonomic nervous system regulating
food intake, glucose uptake by peripheral tissues, and
glucagon secretion. Here, we further demonstrate,
using genetically-modified mice, that the signal
transmitted at the muscle level does not require the
presence of an insulin receptor, but requires the pres-
ence of GLUT4. In addition, activation of glucose
transport is suppressed by expression of the AMPK-DN
in muscle, indicating a requirement for AMP kinase
activity in the stimulation of glucose uptake. This
description of a glucose sensor, able to induce
hypoglycemia in an insulin-independent fashion,
demonstrates an additional complexity in the control
of glucose homeostasis. This sensor may play a par-
ticularly important role in the postprandial state
when a portal-peripheral glucose gradient is estab-
lished. Dysfunction of this sensor may cause
impaired glucose tolerance in the prediabetic or dia-
betic states. Its function may also become progres-
sively blunted in diabetes, when peripheral hyper-
glycemia is less well controlled and a portal-
peripheral gradient more difficult to establish. 
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